A broad-spectrum mRNA vaccine for Chikungunya virus designed by optimizing the full-length structural protein sequence

By optimizing the C protein sequence and combining lipid nanoparticle encapsulation technology, an mRNA-CV-C-E vaccine was designed, which solved the problems of broad-spectrum and insufficient immune response of existing vaccines, and significantly improved the different spectrums of chikungunya viruses The protective effect of the patient achieves more lasting antibody production and viral load control.

CN118561969BActive Publication Date: 2024-11-19INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411054312.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

The existing chikungunya virus vaccine lacks broad-spectrum and cellular immune response levels, and live attenuated vaccines have safety risks, making it difficult to effectively protect viral infections in different lineages.

Method used

By optimizing the design of full-length structural protein sequences, especially codon optimization of C protein sequences, and adding them to the mRNA vaccine of envelope protein targets, the mRNA-CV-C-E vaccine is formed, and the encapsulation of lipid nanoparticles is enhanced. Broad spectrum and immune response effects of vaccines.

Benefits of technology

The mRNA-CV-C-E vaccine showed higher cross-protection among different strains, producing more lasting binding and neutralizing antibodies, significantly improving the protection effect on different lineages, and showing more in mouse models Strong immune response and viral load control capability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118561969B_ABST
    Figure CN118561969B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of mRNA vaccine preparation, and specifically relates to a broad-spectrum mRNA vaccine for Chikungunya virus designed by optimizing the full-length structural protein sequence. Specifically, the present invention provides a polynucleotide, the polynucleotide sequence is shown in SEQ ID NO.2, and the mRNA vaccine contains mRNA obtained by transcription of the sequence shown in SEQ ID NO.2. The vaccine provided by the present invention has a stronger cellular immune response level, and the level of binding antibodies produced after the dosage reaches a certain level is higher and maintained more lastingly, and the neutralizing antibody level also has a certain effect. In terms of broad spectrum, the vaccine produces neutralizing antibodies against pseudoviruses from the West African lineage, the Indian Ocean lineage and the East, Central and South African lineage, and has cross-protection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of mRNA vaccine preparation, and specifically relates to a broad-spectrum mRNA vaccine for Chikungunya virus designed by optimizing the full-length structural protein sequence. Background Art

[0002] Chikungunya virus (CHIKV) is a mosquito-borne virus native to Africa. It belongs to the genus Alphavirus and has a wide range of cell and tissue tropism. It can replicate in most cell types except B and T cells. It spreads throughout the body through severe viremia, mainly causing joint inflammation. Although Chikungunya fever is a self-limiting disease, it can leave serious sequelae and is more harmful to the elderly and children.

[0003] Initially, CHIKV broke out in East Africa, then became prevalent in African countries, then broke out in Southeast Asia, and later broke out in the South Asian subcontinent. There are four main lineages of CHIKV: (1) West Africa; (2) East / Central / South Africa (ECSA); (3) Asian lineage; (4) Indian Ocean lineage. Initially, CHIKV was only transmitted by Aedes aegypti, so only local outbreaks occurred in tropical regions. However, with the emergence of the Indian Ocean lineage, CHIKV can be transmitted by Aedes albopictus distributed in temperate zones, gradually spreading to temperate regions, and there is a trend of global outbreak. Currently, there are almost no safe and effective vaccines available on the market. Only a live attenuated vaccine has been recently launched, but the live attenuated vaccine has safety risks.

[0004] At present, many studies have shown that vaccines designed with a single strain have cross-protection against other lineages. Some studies have found that the serum of recovered patients infected with a certain lineage strain of CHIKV has a protective effect against infection with other lineage strains. In addition, Nature has reported that the study of alphavirus antigenic epitopes found that the main neutralizing epitopes of alphavirus viruses exist on the E2 protein of the envelope protein, and most alphavirus neutralizing epitopes have high homology, which is not only conserved in CHIKV, but also in the alphavirus genus. Based on this, we designed a vaccine based on the conserved envelope protein, mRNA-CV-E (CN117771353B A Chikungunya virus mRNA vaccine targeting envelope protein and its preparation method), by searching for conserved sequences, but the broad spectrum and cellular immune response level of the vaccine still need to be improved. Summary of the invention

[0005] The main purpose of the present invention is to provide a broad-spectrum mRNA vaccine of Chikungunya virus designed by optimizing the full-length structural protein sequence to solve the problems existing in the background technology.

[0006] Specifically, the present invention adopts the following technical solutions:

[0007] A polynucleotide, the polynucleotide sequence is shown as SEQ ID NO.2.

[0008] A protein, which is obtained by transcription and translation of the polynucleotide, and the amino acid sequence of the protein is shown as SEQ ID NO.1.

[0009] A recombinant plasmid contains the polynucleotide.

[0010] Furthermore, UTR sequences are designed at both ends of the polynucleotide in the recombinant plasmid, and the UTR sequences are shown as SEQ ID NO.3 and / or SEQ ID NO.4.

[0011] An engineered bacterium contains the recombinant plasmid.

[0012] An mRNA transcribed from the polynucleotide, wherein the nucleotide sequence of the mRNA is shown as SEQ ID NO.5.

[0013] Lipid nanoparticles loaded with the mRNA.

[0014] The use of the protein, the polynucleotide, the recombinant plasmid, the engineered bacteria, the mRNA or the lipid nanoparticles in the preparation of a Chikungunya virus vaccine.

[0015] Furthermore, the Chikungunya virus is a virus of the West African lineage, the Indian Ocean lineage and the East, Central and South African lineage.

[0016] An mRNA vaccine for Chikungunya virus, wherein the mRNA vaccine contains the mRNA or the lipid nanoparticles.

[0017] A kit comprising the protein, the polynucleotide, the recombinant plasmid, the engineered bacteria, the mRNA, the lipid nanoparticle or the mRNA vaccine.

[0018] Furthermore, the present invention also provides a method for preparing an mRNA vaccine of Chikungunya virus, comprising the following steps:

[0019] S1: construct a recombinant plasmid containing the polynucleotide sequence shown in SEQ ID NO.2;

[0020] S2: The recombinant plasmid is linearized by enzyme digestion, and the linearized template is transcribed in vitro to obtain the mRNA vaccine entity with the sequence as described in SEQ ID NO.5;

[0021] S3: Preparation of vaccine carrier: lipid nanoparticle solution;

[0022] S4: Dissolve the mRNA vaccine in a citric acid buffer, mix it with the lipid nanoparticle solution, and then ultrafilter to obtain the mRNA vaccine.

[0023] The technical effects achieved by the present invention are:

[0024] C protein is the capsid protein of Chikungunya virus. Although it is not suitable to be exposed during the virus infection process, C protein has many T cell epitopes, and virus-like particles may be formed in the presence of C protein to enhance its immunogenicity. Based on this, the present invention designed a conservative C protein sequence based on the conservative amino acids at each amino acid site from 769 strains, and optimized the codons. The optimized C protein sequence was added to the vaccine mRNA-CV-E of the original patent of this team "An mRNA vaccine of Chikungunya virus targeting envelope protein and its preparation method (CN202410215443.6)" to obtain mRNA-CV-CE. Further vaccine evaluation showed that mRNA-CV-CE has a stronger cellular immune response level to inactivated virus stimulation than mRNA-CV-E, and the level of binding antibodies produced after the dose reaches a certain level is higher and more persistent, and the level of neutralizing antibodies also has a certain effect. In terms of broad spectrum, after the dosage reaches a certain level, the cross-protection of mRNA-CV-CE against different strains: South African lineage, Indian Ocean lineage and East Central African lineage is higher than that of mRNA-CV-E. Therefore, the C protein designed in the present invention plays a certain role in the broad spectrum, and it is also very critical to select a conservative sequence for the C protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Schematic diagram of mRNA-CV-CE;

[0026] Figure 2 Figure 2. mRNA detection results; a) Electrophoresis of in vitro transcribed RNA, lane 1: mRNA-CV-CE; b) Encapsulation verification, lane 1: mRNA-LNP, lane 2: mRNA-LNP after treatment with tritonx-100 to fully release mRNA; c) Particle size distribution of prepared mRNA-LNP.

[0027] Figure 3 WB experiment pictures after mRNA-CV-CE transfected cells; a) mRNA-CV-CE expression in 293T / 17 cells compared with the Mirus kit; b) mRNA-CV-CE expression in Vero cells compared with the Mirus kit (MIR2225).

[0028] Figure 4Vero cell immunofluorescence image; DAPI indicates cell nucleus staining, which is blue; E1 is stained with viral E1 protein, which is green; Merge: a merged image of cell nucleus staining and viral E1 protein expression in the cytoplasm.

[0029] Figure 5 Statistical graph of body weight changes of Balb / c mice within five days after immunization with different doses;

[0030] Figure 6 After mice were immunized with mRNA-CV-CE at doses of 4 μg, 8 μg, and 15 μg, sera were collected on days 7, 14, 21, and 28 to detect IgG binding antibody titers;

[0031] Figure 7 Representative sample pictures of the number of spots produced by the two vaccine groups in the Elispot experiment against IFN-γ, IL-2 and IL-4, using inactivated virus as a stimulant and compared with mRNA-CV-E; Mock is a negative control without stimulation with a stimulant, and the control group is a control group injected with only empty LNP.

[0032] Figure 8 Elispot experiments generated statistical graphs of the number of relevant cytokine spots from five samples in each group at each dose of the two vaccines, with each point representing a mouse sample.

[0033] Fig. 9 Figure 3 Live virus neutralization experiment of Balb / c mouse serum on days 7, 14, 21 and 28 after immunization at different doses. The original strain is the strain isolated from the Ruili epidemic in Yunnan, genbank number: H670649.1, and the mouse-adapted strain is the derived adaptive mutant strain obtained by culturing the original strain in mice.

[0034] Fig.10 Neutralization antibody graphs of mRNA-CV-CE and mRNA-CV-E at doses of 4 μg, 8 μg, and 15 μg against pseudoviruses from the South African lineage, the Indian Ocean lineage, and the East Central African lineage;

[0035] Fig.11 Statistical chart of joint swelling in the four limbs (left forelimb; right forelimb; left hindlimb; right hindlimb) of mice within seven days after infection.

[0036] Fig.12 Detection chart of viral load in the blood of mice in each dose group after mice were challenged with the virus;

[0037] Fig.13 Virus loads in various tissues of mice on the seventh day after virus infection;

[0038] Fig.14H&E staining of joint tissues, spleen, muscle and heart in each vaccine dose group and the control group.

[0039] Fig.15 Pathological scoring diagram of joints, spleen, and muscle tissues of each vaccine dose group and the control group. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described below in conjunction with the embodiments. It should be understood that the embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. The interpretation of some materials in the present invention is shown in Table 1 below, and all materials in the present invention can be purchased from the market.

[0041] Table 1 Sequence information

[0042] name Serial Number C-E3-E2-6k-E1 protein SEQ ID NO: 1 C-E3-E2-6k-E1 polynucleotide SEQ ID NO: 2 5'UTR SEQ ID NO: 3 3'UTR SEQ ID NO: 4 mRNA sequences SEQ ID NO: 5 Example 1

[0043] 1. Vaccine preparation

[0044] The full-length structural proteins of CHIKV were searched in the NCBI Virus database, and the amino acid sequences of 769 full-length structural proteins from different lineages were obtained. The amino acid sequences were aligned, with a total of 1248 amino acids. The most common amino acids at each amino acid site were selected, and the 1248 conserved amino acids were reassembled in order into a new conserved amino acid sequence (SEQ ID NO: 1). Codon optimization was performed according to human codon preference to obtain a DNA sequence (SEQ ID NO: 2). The full-length structural protein C-E3-E2-6k-E1 sequence was constructed into a plasmid PUC57 containing a T7 promoter, 5'UTR (SEQ ID NO: 3), 3'UTR (SEQ ID NO: 3) and 100 PolyA (PUC57-T7-5UTR-C-E3-E2-6k-E1-3UTR-PolyA). Top10 strains were used for plasmid amplification. After plasmid extraction, BsaI was used for linearization. The linearized template was precipitated with 70% volume of isopropanol and washed with 70% ethanol. The linearized template was transcribed in vitro using a commercial kit. Before transcription, the raw material UTP was completely replaced with N1-methyl pseudouridine triphosphate (N1-Me-pUTP). After transcription, mRNA (SEQ ID NO: 5) was obtained. See Figure 1 Abbreviated as "mRNA-CV-CE".

[0045] 2. Lipid Nanoparticle (LNP) Encapsulation

[0046] Dissolve mRNA in 50mM citric acid buffer at pH 4 to a final concentration of 108ng / μL. Then, a lipid mixed solution was prepared: SM102, DMG-PEG2000, DSPC, and cholesterol were mixed and dissolved in anhydrous ethanol solution at a molar ratio of 50%, 1.5%, 10%, and 38.5%, and the lipid-ethanol solution and the mRNA-citric acid solution were filtered through a 0.22 μm microporous filter membrane, respectively. According to the molar ratio of the phosphorus content in the mRNA to the N element content in SM102 of 1:8, they were mixed using a microfluidic instrument, and the flow rate ratio was 15 mL / min: 5 mL / min for the buffer phase: ethanol phase. The obtained mRNA-LNP was immediately diluted with 15 ml of the above-mentioned citric acid buffer and ultrafiltered with a 100KD ultrafiltration tube with a centrifugal force of 3000 g. After ultrafiltration to 1 / 4 volume, 20 mM Tris-HCl buffer (PH=7.5) was added to 15 mL. After repeated two times, the concentration and encapsulation efficiency were measured.

[0047] Then, after verifying its expression effect in 293T / 17 cells and Vero cells respectively, the effectiveness of the vaccine was demonstrated through serum binding antibodies, serum neutralizing antibodies, and virus protection experiments after immunizing BALB / c mice.

[0048] mRNA-CV-CE vaccine effects:

[0049] Electrophoresis of in vitro transcribed RNA and verification of successful mRNA-LNP preparation

[0050] Depend on Figure 2 It can be seen that the transcribed RNA has no obvious degradation and mixed bands, and mRNA-LNP is successfully prepared with an average particle size of about 100nm.

[0051] Verification of mRNA-CV-CE-LNP cell-level expression

[0052] like Figure 3 It can be seen that mRNA-CV-CE was expressed in both 293T / 17 cells and Vero cells after transfection, and the untransfected negative control (-) did not have the target band.

[0053] Figure 4 Immunofluorescence experiments showed that mRNA-CV-CE was successfully expressed in Vero cells and was mainly expressed in cells and on the cell membrane. No target protein was found in the negative control group.

[0054] Body weight changes of BALB / c mice after vaccination

[0055] Figure 5As can be seen, the body weight of the immunized mice and the control group injected with empty LNP decreased slightly and then continued to increase overall, and the body temperature was normal, indicating that the vaccine had no obvious toxicity.

[0056] After BALB / c mice were immunized with mRNA-CV-CE, the titer of serum antibodies binding to E2 protein antigen was significantly increased: two immunizations were performed at 0d and 14d respectively.

[0057] Figure 6 Serum was collected on days 7, 14, 21, and 28 after mice were immunized with mRNA-CV-CE to detect IgG binding antibody titers; Figure 6 It can be seen that compared with mRNA-CV-E, the binding antibody level of mRNA-CV-CE is significantly more persistent after reaching a certain dose, and the maximum level that can be achieved is significantly higher than that of mRNA-CV-E.

[0058] mRNA-CV-CE induces strong T cell immunity in Balb / c mice

[0059] Figure 7 and Figure 8 ,ELISpot experiments were performed using inactivated viruses isolated from the Ruili epidemic in Yunnan as stimuli, and the number of specific spots of IL-2, IL-4, and IFN-γ were measured respectively. The levels of IFN-γ and IL-2 were significantly higher than those of IL-4, proving that both mRNA-CV-CE and mRNA-CV-E were mainly Th1 type reactions. However, since there are also T cell epitopes on the C protein, the results of mRNA-CV-CE were significantly higher than those of mRNA-CV-E.

[0060] mRNA-CV-CE immunization produces certain neutralizing antibodies against CHIKV

[0061] Fig. 9 The serum of Balb / c mice was collected on days 7, 14, 21, and 28 after immunization for live virus neutralization experiments. The live viruses used were the Yunnan Ruili epidemic isolate (MH670649.1) and the mouse-adapted mutant strain. Fig. 9 It can be seen that the neutralizing antibody increased significantly 21 days after the first immunization, and a certain amount of neutralizing antibodies were produced against both strains. Compared with mRNA-CV-E, after reaching a certain dose, the neutralizing antibody level was significantly higher than that of mRNA-CV-E, and lasted longer. At a dose of 15 ug, 28 days after the second immunization, mRNA-CV-CE reached a peak value, which was higher than the peak value of mRNA-CV-E, while the neutralizing antibody level of mRNA-CV-E began to decline 21 days after the second immunization. Therefore, after reaching a certain dose, the neutralizing antibody of mRNA-CV-CE, therefore mRNA-CV-CE can produce higher levels of neutralizing antibodies.

[0062] 7. Broad-spectrum vaccine validation

[0063] Fig.10 Neutralization of pseudovirus antibodies from West African lineage, Indian Ocean lineage and East Central African lineage was compared with mRNA-CV-CE and mRNA-CV-E at doses of 4 μg, 8 μg and 15 μg. Fig.10 It can be seen that both mRNA-CV-CE and mRNA-CV-E can produce broad-spectrum cross-protective antibodies, but in mRNA-CV-CE with the conservative C protein added, as the dose increases, the neutralizing antibodies against each strain are significantly higher than mRNA-CV-E. Therefore, under the premise of sufficient dose, mRNA-CV-CE has a greater broad-spectrum potential.

[0064] Virus challenge experiment in Balb / c mice after immunization

[0065] Fig.11 The swollen joints of the limbs of mice within seven days after the virus attack were as follows: left forelimb; right forelimb; left hindlimb; right hindlimb. There was no joint swelling in the vaccine group after the virus attack, and the control group was not obvious either.

[0066] mRNA-CV-CE completely controls the emergence of viremia in mice infected with CHIKV

[0067] Fig.12 The viral load in the blood of mice in each dose group after the infection was detected. The results were the same as those of mRNA-CV-E. The high, medium and low dose groups were able to completely control the occurrence of viremia after the infection. In contrast, the empty LNP group and the control group had more severe viremia on the first day after infection. This proves that mRNA-CV-CE has a good protective effect on BALB / c.

[0068] Fig.13 The viral loads in various tissues of mice on the seventh day after infection were similar to those of mRNA-CV-E. Fig.12 It can be seen that mice immunized with mRNA-CV-CE can clear the viral load of most tissues and organs after CHIKV challenge, and the viral load of the spleen and the hind paw muscles and hind paws injected in situ was significantly decreased, indicating that the vaccine can effectively clear or significantly reduce the viral load of systemic tissues and organs.

[0069] 9. Pathological damage to joint tissue

[0070] Fig.14 and Fig.15, joint tissue is considered to be the main infection organ of CHIKV, and arthritis is the main symptom of CHIKV, so the pathological damage of joints is very important. As can be seen from the figure, both mRNA-CV-CE and mRNA-CV-E significantly controlled the pathological damage of joint tissues, but from the perspective of pathological scores, after mRNA-CV-CE reached a certain dose, the pathological score was significantly lower, that is, the degree of pathological damage was lower, so mRNA-CV-CE was more effective than mRNA-CV-E when it reached a certain dose. In spleen, muscle, and heart tissues, both mRNA-CV-CE and mRNA-CV-E significantly reduced the pathological damage, especially in heart tissue, the pathological damage of mRNA-CV-CE was more significantly reduced than that of mRNA-CV-E.

Claims

1. A polynucleotide for preparing a Chikungunya virus vaccine, characterized in that: The polynucleotide sequence is shown as SEQ ID NO.2, and the Chikungunya virus is a virus of the West African lineage, the Indian Ocean lineage and the East, Central and South African lineage.

2. A recombinant plasmid, characterized in that: Containing the polynucleotide according to claim 1.

3. The recombinant plasmid according to claim 2, characterized in that UTR sequences are designed at both ends of the polynucleotide, and the UTR sequences are shown in SEQ ID NO.3 and / or SEQ ID NO.

4.

4. An engineered bacterium, characterized in that: Containing the recombinant plasmid according to claim 2 or 3.

5. An mRNA transcribed from the polynucleotide of claim 1, characterized in that: The nucleotide sequence of the mRNA is shown in SEQ ID NO.

5.

6. Lipid nanoparticles loaded with the mRNA of claim 5.

7. Use of the polynucleotide according to claim 1, the recombinant plasmid according to claim 2 or 3, the engineered bacteria according to claim 4, the mRNA according to claim 5 or the lipid nanoparticles according to claim 6 in the preparation of a Chikungunya virus mRNA vaccine, characterized in that: The Chikungunya virus is a virus of the West African lineage, the Indian Ocean lineage and the East Central and South African lineage.

8. An mRNA vaccine for Chikungunya virus, comprising the mRNA of claim 5 or the lipid nanoparticles of claim 6.

9. A kit, characterized in that: The kit comprises the polynucleotide according to claim 1, the recombinant plasmid according to claim 2 or 3, the engineered bacteria according to claim 4, the mRNA according to claim 5, the lipid nanoparticles according to claim 6 or the mRNA vaccine according to claim 8.

Citation Information

Patent Citations

  • An mRNA vaccine of Chikungunya virus targeting envelope protein and preparation method thereof

    CN117771353B

  • Vaccine composition comprising an inactivated chikungunya virus strain

    CN103796676A

  • Cis replicon RNA construct for efficiently expressing target protein

    CN112852841A

  • Chikungunya virus mRNA vaccine taking envelope protein as target and preparation method of chikungunya virus mRNA vaccine

    CN117771353A

  • Chikv RNA vaccines

    US20200368344A1